Content area
Full Text
Bone Marrow Transplantation (2016) 51, 13071312 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0268-3369/16
http://www.nature.com/bmt
Web End =www.nature.com/bmt
J Gayoso1,2, P Balsalobre1,2, MJ Pascual3, C Castilla-Llorente4, L Lpez-Corral5, M Kwon1,2, D Serrano1,2, JL Piana6, P Herrera7, C Ferr8, C Pascual1,2, I Heras4, P Montesinos9, A Zabalza10, L Bento11, A Figuera12, I Buo1,2 and JL Dez-Martn1,2 on behalf of GETH (Spanish Group for Hematopoietic Transplantation)
Relapsed or refractory Hodgkin lymphoma (advanced HL) still remains a therapeutic challenge. Recently, unmanipulated haploidentical related donor transplant with reduced conditioning regimen (HAPLO-RIC) and post-transplant cyclophosphamide (PT-Cy) as GvHD prophylaxis has became a promising rescue strategy potentially available to almost every patient. This paper reports our multicenter experience using an IV busulfan-based HAPLO-RIC regimen and PT-Cy in the treatment of 43 patients with advanced HL. Engraftment occurred in 42 patients (97.5%), with a median time to neutrophil and platelet recovery of 18 and26 days. Cumulative incidences of grades IIIV acute GvHD and chronic GvHD were 39% and 19%, respectively. With a median follow-up of 25.5 months for survivors, 27 patients are alive, with 22 of them disease free. Cumulative incidences of 1-year non-relapse mortality and relapse at 2 years were 21% and 24%, respectively. The estimated 2-year event-free survival (EFS) and overall survival (OS) were 48% and 58%, respectively. CR prior to HAPLO-RIC correlated with better EFS (78.5% vs 33.5%; P = 0.015) and OS (86% vs 46%; P = 0.044). Our ndings further conrm prior reports using HAPLO-RIC in advanced HL in a multicenter
Bone Marrow Transplantation (2016) 51, 13071312; doi:http://dx.doi.org/10.1038/bmt.2016.115
Web End =10.1038/bmt.2016.115 ; published online 9 May 2016
INTRODUCTION
Currently, Hodgkin lymphoma (HL) is a curable disease for 480%
of the patients following modern chemotherapy regimens, associated or not with radiotherapy.1 However, relapsed or refractory patients remain a therapeutic challenge. In recent years, salvage strategies, including intensication therapy followed by autologous hematopoietic stem cell transplantation (HSCT), have offered a curative option for 4050% of these patients, mostly those with chemo-sensitive disease.1 Moreover, allogeneic HSCT with an HLA-identical related or unrelated donor can rescue a further proportion of relapsed/refractory cases, either employing myeloablative conditioning (MAC) or reduced intensity conditioning (RIC) regimens.27 Unfortunately, results are still modest with either approach owing to a high relapse rate...